Accure develops integrated nano vesicle technologies that leverage patients' biomarker profiles and vesicles' natural delivery capabilities to enable precision therapies targeted to the right cells for the right patients. The platform combines advantages from AI-powered protein design, rapid nano vesicle analysis with an easy-to-scale production system, to improve the success rates of RNA and protein therapeutics.

 

Accure's initial technology originated from the Harvard Medical School and Massachusetts General Hospital. Together with clinical and industry partners, Accure is developing unique solutions for cancer, neurodegeneration and other complex diseases.